Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06182280 · ClinicalTrials.gov registry record · NA
Transmaculine One-on-One and Group Empowerment for Targeted HIV Reduction
A NA study, sponsored by Fenway Community Health.
- Not yet
- Registry status
- NA
- Development phase
- 375
- Enrollment target
NCT06182280: Clinical Trial NA study, sponsored by Fenway Community Health.
NCT06182280 is a NA study that has not yet begun recruiting, run by Fenway Community Health. The registered enrollment target is 375 participants, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (73% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06182280, a NA study, has not yet begun recruiting, sponsored by Fenway Community Health.
- NOT YET RECRUITING
- Registry status
- NA
- Development phase
- 375 participants
- Enrollment target
Study Summary
Transgender masculine and gender diverse people who have sex with men (TMSM) have an increased risk of HIV and face unique barriers engaging in prevention services. Digitally delivered support interventions addressing HIV prevention barriers delivered by peers in one-on-one or small-group settings may be effective at increasing PrEP engagement. This study examines the independent and combined effects of individual and group-based peer-support interventions on PrEP outcomes. Participants will be randomly assigned to receive: (i) standard-of-care HIV prevention information, (ii) a one-on-one healthy lifestyle intervention tailored for transgender masculine people, (iii) a peer-group based healthy lifestyle intervention for transgender masculine people, or (iv) both the one-on-one and group-based interventions delivered together. The hypotheses are that the individual group-based interventions will result in higher PrEP uptake and persistence than the standard of care and that the combined interventions will be more effective than receiving one individual intervention.
Primary Outcome
Uptake of new PrEP prescriptions during the study intervention and follow-up period as measured by biomarker sampling collected by dried blood spots.
Interventions
- BEHAVIORAL PrEP4T
- BEHAVIORAL LS4TM
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 375 participants |
| Start Date | 2024-01 |
| Est. Completion | 2027-06 |
| Phase | NA |
What is known before NCT06182280 opens enrollment
NCT06182280 is an interventional study that assigns participants to a tested intervention. The registered 375 participants enrollment target is mid-sized for trials with a published cap, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (73% lower).
The record links to 0 conditions, and to 2 interventions - of which PrEP4T is the first listed.
NCT06182280 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT06182280 about?
NCT06182280 is a clinical study titled "Transmaculine One-on-One and Group Empowerment for Targeted HIV Reduction". Transgender masculine and gender diverse people who have sex with men (TMSM) have an increased risk of HIV and face unique barriers engaging in prevention services. Digitally delivered support interventions addressing HIV prevention barriers delivered by peers in one-on-one or small-group settings m...
What is the current status of trial NCT06182280?
This trial is currently not yet recruiting. It is a NA study. The enrollment target is 375 participants. The study started on 2024-01. Estimated completion is 2027-06.
What interventions are being tested in trial NCT06182280?
The interventions under investigation include: PrEP4T (BEHAVIORAL), LS4TM (BEHAVIORAL).
Who is sponsoring clinical trial NCT06182280?
This trial is sponsored by Fenway Community Health, which has 14 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT06182280's enrollment target sits among peer trials
375 276th of 2000 higher than 1,721 of 2,000 other NA trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other NA trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03686124 · 375 participants · Phase 1
ACTengine® IMA203/IMA203CD8 as Monotherapy or in Combination With Nivolumab in Recurrent and/or Refractory Solid Tumors
- NCT04059172 · 375 participants · Early Phase 1
Efficacy of Combined Ibuprofen and Acetaminophen Therapy Versus Ibuprofen Alone Versus Placebo Alone for Pain Management
- NCT04134923 · 375 participants
Imaging Biomarkers in Preclinical and Symptomatic AD
- NCT04569747 · 375 participants · Phase 2
A Single Arm Phase II Study of ADjuvant Endocrine Therapy, Pertuzumab, and Trastuzumab for Patients With Anatomic Stage I Hormone Receptor-positive, HER2-positive Breast Cancer
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia